BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23384223)

  • 1. Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model.
    Harter PN; Dützmann S; Drott U; Zachskorn C; Hattingen E; Capper D; Gessler F; Senft C; Seifert V; Plate KH; Kögel D; Mittelbronn M
    Neuropathology; 2013 Oct; 33(5):515-25. PubMed ID: 23384223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells.
    Gessler F; Voss V; Dützmann S; Seifert V; Gerlach R; Kögel D
    Neuroscience; 2010 Feb; 165(4):1312-22. PubMed ID: 19958818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contribution of tumor and host tissue factor expression to oncogene-driven gliomagenesis.
    Magnus N; Meehan B; Garnier D; Hashemi M; Montermini L; Lee TH; Milsom C; Pawlinski R; Ohlfest J; Anderson M; Mackman N; Rak J
    Biochem Biophys Res Commun; 2014 Nov; 454(2):262-8. PubMed ID: 25450387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo.
    Giussani C; Carrabba G; Pluderi M; Lucini V; Pannacci M; Caronzolo D; Costa F; Minotti M; Tomei G; Villani R; Carroll RS; Bikfalvi A; Bello L
    Cancer Res; 2003 May; 63(10):2499-505. PubMed ID: 12750272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
    Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
    Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
    Pisati F; Belicchi M; Acerbi F; Marchesi C; Giussani C; Gavina M; Javerzat S; Hagedorn M; Carrabba G; Lucini V; Gaini SM; Bresolin N; Bello L; Bikfalvi A; Torrente Y
    Cancer Res; 2007 Apr; 67(7):3054-63. PubMed ID: 17409412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model.
    Takashima H; Tsuji AB; Saga T; Yasunaga M; Koga Y; Kuroda JI; Yano S; Kuratsu JI; Matsumura Y
    Sci Rep; 2017 Sep; 7(1):12341. PubMed ID: 28951589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
    Breij EC; de Goeij BE; Verploegen S; Schuurhuis DH; Amirkhosravi A; Francis J; Miller VB; Houtkamp M; Bleeker WK; Satijn D; Parren PW
    Cancer Res; 2014 Feb; 74(4):1214-26. PubMed ID: 24371232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
    Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
    Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumoral RANKL activates astrocytes that promote glioma cell invasion through cytokine signaling.
    Kim JK; Jin X; Sohn YW; Jin X; Jeon HY; Kim EJ; Ham SW; Jeon HM; Chang SY; Oh SY; Yin J; Kim SH; Park JB; Nakano I; Kim H
    Cancer Lett; 2014 Oct; 353(2):194-200. PubMed ID: 25079688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
    Lemke D; Pfenning PN; Sahm F; Klein AC; Kempf T; Warnken U; Schnölzer M; Tudoran R; Weller M; Platten M; Wick W
    Clin Cancer Res; 2012 Jan; 18(1):105-17. PubMed ID: 22080438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
    Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K
    Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
    Hui AM; Zhang W; Chen W; Xi D; Purow B; Friedman GC; Fine HA
    Cancer Res; 2004 Dec; 64(24):9115-23. PubMed ID: 15604281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential ability of tissue factor antibody clones on detection of tissue factor in blood cells and microparticles.
    Basavaraj MG; Olsen JO; Østerud B; Hansen JB
    Thromb Res; 2012 Sep; 130(3):538-46. PubMed ID: 22728024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
    Wang L; Liu Q; Zhao H; Cui K; Yao L; Nie F; Jin G; Hao A; Wong ST
    J Neurosci Res; 2013 Jan; 91(1):128-37. PubMed ID: 23115024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
    Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
    Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling tumor invasion: bevacizumab and BMP4 for glioblastoma.
    Rahman M; Azari H; Deleyrolle L; Millette S; Zeng H; Reynolds BA
    Future Oncol; 2013 Sep; 9(9):1389-96. PubMed ID: 23980685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.